1
|
El-Azazy M, El-Shafie AS, Morsy H. Biochar of Spent Coffee Grounds as Per Se and Impregnated with TiO 2: Promising Waste-Derived Adsorbents for Balofloxacin. Molecules 2021; 26:molecules26082295. [PMID: 33921054 PMCID: PMC8071459 DOI: 10.3390/molecules26082295] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2021] [Revised: 04/09/2021] [Accepted: 04/13/2021] [Indexed: 12/22/2022] Open
Abstract
Biochars (BC) of spent coffee grounds, both pristine (SCBC) and impregnated with titanium oxide (TiO2@SCBC) were exploited as environmentally friendly and economical sorbents for the fluroquinolone antibiotic balofloxacin (BALX). Surface morphology, functional moieties, and thermal stabilities of both adsorbents were scrutinized using SEM, EDS, TEM, BET, FTIR, Raman, and TG/dT analyses. BET analysis indicated that the impregnation with TiO2 has increased the surface area (50.54 m2/g) and decreased the pore size and volume. Batch adsorption experiments were completed in lights of the experimental set-up of Plackett-Burman design (PBD). Two responses were maximized; the % removal (%R) and the adsorption capacity (qe, mg/g) as a function of four variables: pH, adsorbent dosage (AD), BALX concentration ([BALX]), and contact time (CT). %R of 68.34% and 91.78% were accomplished using the pristine and TiO2@SCBC, respectively. Equilibrium isotherms indicated that Freundlich model was of a perfect fit for adsorption of BALX onto both adsorbents. Maximum adsorption capacity (qmax) of 142.55 mg/g for SCBC and 196.73 mg/g for the TiO2@SCBC. Kinetics of the adsorption process were best demonstrated using the pseudo-second order (PSO) model. The adsorption-desorption studies showed that both adsorbents could be restored with the adsorption efficiency being conserved up to 66.32% after the fifth cycles.
Collapse
|
2
|
Marques CSF, Barreto NS, de Oliveira SSC, Santos ALS, Branquinha MH, de Sousa DP, Castro M, Andrade LN, Pereira MM, da Silva CF, Chaud MV, Jain S, Fricks AT, Souto EB, Severino P. β-Cyclodextrin/Isopentyl Caffeate Inclusion Complex: Synthesis, Characterization and Antileishmanial Activity. Molecules 2020; 25:E4181. [PMID: 32932660 PMCID: PMC7570699 DOI: 10.3390/molecules25184181] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2020] [Revised: 09/04/2020] [Accepted: 09/09/2020] [Indexed: 11/16/2022] Open
Abstract
Isopentyl caffeate (ICaf) is a bioactive ester widely distributed in nature. Our patented work has shown promising results of this molecule against Leishmania. However, ICaf shows poor solubility, which limits its usage in clinical settings. In this work, we have proposed the development of an inclusion complex of ICaf in β-cyclodextrin (β-CD), with the aim to improve the drug solubility, and thus, its bioavailability. The inclusion complex (ICaf:β-CD) was developed applying three distinct methods, i.e., physical mixture (PM), kneading (KN) or co-evaporation (CO) in different molar proportions (0.25:1, 1:1 and 2:1). Characterization of the complexes was carried out by thermal analysis, Fourier-transform infrared spectroscopy (FT-IR), scanning electron microscopy (SEM) and molecular docking. The ICaf:β-CD complex in a molar ratio of 1:1 obtained by CO showed the best complexation and, therefore, was selected for further analysis. Solubility assay showed a marked improvement in the ICaf:β-CD (CO, 1:1) solubility profile when compared to the pure ICaf compound. Cell proliferation assay using ICaf:β-CD complex showed an IC50 of 3.8 and 2.7 µg/mL against L. amazonesis and L. chagasi promastigotes, respectively. These results demonstrate the great potential of the inclusion complex to improve the treatment options for visceral and cutaneous leishmaniases.
Collapse
Affiliation(s)
- Carine S. F. Marques
- Postgraduation in Biotechnology Program, Industrial and Institute of Technology and Research (ITP), Tiradentes University (UNIT), Av. Murilo Dantas, 300, 49010-390 Aracaju, Brazil; (C.S.F.M.); (N.S.B.); (S.J.); (A.T.F.)
| | - Nathalia S. Barreto
- Postgraduation in Biotechnology Program, Industrial and Institute of Technology and Research (ITP), Tiradentes University (UNIT), Av. Murilo Dantas, 300, 49010-390 Aracaju, Brazil; (C.S.F.M.); (N.S.B.); (S.J.); (A.T.F.)
| | - Simone S. C. de Oliveira
- Departament of General Microbiology, Institute of Microbiology Paulo de Góes, Federal University l Rio de Janeiro, 21941-918 Rio de Janeiro, RJ, Brazil; (S.S.C.d.O.); (A.L.S.S.); (M.H.B.)
| | - André L. S. Santos
- Departament of General Microbiology, Institute of Microbiology Paulo de Góes, Federal University l Rio de Janeiro, 21941-918 Rio de Janeiro, RJ, Brazil; (S.S.C.d.O.); (A.L.S.S.); (M.H.B.)
| | - Marta H. Branquinha
- Departament of General Microbiology, Institute of Microbiology Paulo de Góes, Federal University l Rio de Janeiro, 21941-918 Rio de Janeiro, RJ, Brazil; (S.S.C.d.O.); (A.L.S.S.); (M.H.B.)
| | - Damião P. de Sousa
- Department of Pharmaceutical Sciences, Federal University of Paraíba, 58051-900 Paraíba, Brazil; (D.P.d.S.); (M.C.)
| | - Mayara Castro
- Department of Pharmaceutical Sciences, Federal University of Paraíba, 58051-900 Paraíba, Brazil; (D.P.d.S.); (M.C.)
| | - Luciana N. Andrade
- Department of Medicine, Federal University of Sergipe, CEP 49400-000 Lagarto, Sergipe, Brazil;
| | - Matheus M. Pereira
- CICECO-Aveiro Institute of Materials, Departamento f Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal;
| | - Classius F. da Silva
- Department of Exact Sciences and Earth, Federal University of São Paulo (UNIFESP), 09972-270 Diadema CEP, Brazil;
| | - Marco V. Chaud
- Department of Technological and Environmental Processes, Sorocaba University (UNISO), Rod. Raposo Tavares, Km 92.5, 18023-000 Sorocaba, Brazil;
| | - Sona Jain
- Postgraduation in Biotechnology Program, Industrial and Institute of Technology and Research (ITP), Tiradentes University (UNIT), Av. Murilo Dantas, 300, 49010-390 Aracaju, Brazil; (C.S.F.M.); (N.S.B.); (S.J.); (A.T.F.)
| | - Alini T. Fricks
- Postgraduation in Biotechnology Program, Industrial and Institute of Technology and Research (ITP), Tiradentes University (UNIT), Av. Murilo Dantas, 300, 49010-390 Aracaju, Brazil; (C.S.F.M.); (N.S.B.); (S.J.); (A.T.F.)
| | - Eliana B. Souto
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Pólo das Ciênciasda Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal
- CEB-Centre of Biological Engineering, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal
| | - Patricia Severino
- Postgraduation in Biotechnology Program, Industrial and Institute of Technology and Research (ITP), Tiradentes University (UNIT), Av. Murilo Dantas, 300, 49010-390 Aracaju, Brazil; (C.S.F.M.); (N.S.B.); (S.J.); (A.T.F.)
- Center for Biomedical Engineering, Department of Medicine, Brigham and Women′s Hospital, Harvard Medical School, 65 Landsdowne Street, Cambridge, MA 02139, USA
- Tiradentes Institute, 150 Mt Vernon St, Dorchester, MA 02125, USA
| |
Collapse
|